Project Grant R01CA293059
Award Date
5/7/25
Completion Date
4/30/30
Dollars Obligated
$506K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
Trustees of Indiana University was awarded a $951,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research titled "Regulation of Ovarian Cancer Stem Cell Niche by Cancer-Associated Fibroblasts." The grant period is from June 15, 2023 to June 14, 2027. Through this award, Indiana University researchers will investigate medical solutions related to ovarian cancer by exploring the...
This $1,489,868.00 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support the "Ovarian Cancer Academy: Advancing Ovarian Cancer Research through Mentorship, Networking, and Collaborations" at Indiana University in Bloomington, IN. The grant, with a performance period from September 30, 2025 to September 29, 2029, aims to transform healthcare for military service members and the...
This $612,288 federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research by the University of Wisconsin-Madison on the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche for high-grade serous ovarian cancer (HGSOC). The award, granted on December 11, 2024, will fund this 5-year research project running through November 30, 2029. The University of Wisconsin System, a prominent academic research...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will provide $811,500.00 over a 5-year period beginning September 1, 2024 to develop and implement a comprehensive platform for patient-specific mechanistic tumor modeling. The key products and services to be delivered include: Merging bioinformatics software for single-cell and spatial multi-omics data analysis (COGAPS, PROJECTR, SPACEMARKERS, DOMINO) with the PhysiCell agent-based...
This $2,073,138 Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), is focused on discovering a new class of tumor antigens and T-cell receptors (TCRs) targeting platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The primary awardee, the University of California, Los Angeles (UCLA), will leverage long-read RNA sequencing, immunopeptidomics, and computational epitope prediction to identify cancer-specific peptide...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the role of the protein FGF21 in mediating musculoskeletal wasting associated with metastatic colorectal cancer (CRC). The $423,084 award to the Trustees of Indiana University, doing business as Indiana University Indianapolis, will fund a 5-year study to: 1) examine how FGF21 impacts bone loss in advanced CRC, 2) determine the mechanisms by which FGF21...
This $577,034 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to investigate the relationship between the physical properties of the metastatic microenvironment and the efficacy of the immune system's mechanosurveillance mechanisms in controlling cancer cell growth. The principal investigators, located at the Sloan-Kettering Institute for Cancer Research and collaborating with researchers at Florida State University and...
This Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program will support research to investigate how changes in the pre-metastatic niche (PMN) facilitate breast cancer metastasis. The total award amount is $521,240 over the project period from Sep 1, 2024 to Aug 31, 2029. The research aims to identify critical events within the PMN that enable metastatic tumor cell colonization, promote phenotypic heterogeneity, and contribute to drug resistance....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis, aims to investigate the role of Heat Shock Factor 1 (HSF1) in regulating immune cell infiltration into metastatic breast tumors. The $378,444 award, effective from April 1, 2025 to March 31, 2030, will fund three key research objectives: Determining how HSF1 activity impacts the recruitment of immune cells,...
The National Cancer Institute (NCI) awarded a 5-year, $465,020 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Maryland, Baltimore (UMB) to investigate how chemotherapy used to treat epithelial ovarian cancer (OC) can paradoxically promote metastatic spread. The research aims to define the molecular mechanisms by which chemotherapy activates tumor-associated membrane-anchored serine proteases (MASPs) that enable the establishment of favorable...